6 documents found, page 1 of 1
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisati...
Antunes, Liliana; Rojas-Castro, Madelyn; Lozano, Marcos; Martínez-Baz, Iván; Leroux-Roels, Isabel; Borg, Maria-Louise; Oroszi, BeatrixWe estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days ...
Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adul...
Antunes, Liliana; Mazagatos, Clara; Martínez‐Baz, Iván; Naesens, Reinout; Borg, Maria‐Louise; Petrović, Goranka; Fatukasi, Terra; Jancoriene, LigitaWe conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between ...
Vaccine effectiveness against influenza hospitalisation in adults during the 20...
Rose, Angela M. C.; Pozo, Francisco; Martínez‐Baz, Iván; Mazagatos, Clara; Bossuyt, Nathalie; Cauchi, John Paul; Petrović, Goranka; Loghin, Isabela I.We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (...
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalis...
Antunes, Liliana; Mazagatos, Clara; Martínez-Baz, Iván; Gómez, Verónica; Borg, Maria-Louise; Petrović, Goranka; Duffy, Róisín; Dufrasne, François EThe European Medicines Agency (EMA) authorised four adapted bivalent mRNA COVID-19 vaccines for use against COVID-19 in September/October 2022: Comirnaty (BNT162b2; Pfizer-BioNTech) and Spikevax (mRNA-1273; Moderna) Original/Omicron BA.1 and Original/Omicron BA.4–5 [1]. During autumn 2022, all European Union/European Economic Area (EU/EEA) countries had vaccination campaigns in place to administer a booster dos...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) d...
Rose, Angela M.C.; Nicolay, Nathalie; Sandonis Martín, Virginia; Mazagatos, Clara; Petrović, Goranka; Baruch, Joaquin; Denayer, Sarah; Seyler, LucieIntroduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) d...
Rose, Angela M.C.; Nicolay, Nathalie; Sandonis Martín, Virginia; Mazagatos, Clara; Petrović, Goranka; Niessen, F Annabel; Machado, AusendaIntroduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. Methods: Forty-six participati...